



Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- [Lumos Pharma, Inc.](https://www.lumos-pharma.com/) (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st.

Event: **Piper Sandler 34th Annual Healthcare Conference – November 29th – December 1st**
Presentation: Lumos Pharma Fireside Chat November 30th at 2:00-2:25 PM (EST)
Webcast link: [Here](#)
1x1 Meetings: Management will be available for one-on-one meetings on November 30th

The webcast for the presentation can also be found on the Company's website under "[Events & Presentations](#)" in the Investors & Media section. Please contact your Piper Sandler salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowthH210 Trial, a PK/PD trial, the OraGrowthH212 Trial, and a switch trial, the OraGrowthH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.



Source: Lumos Pharma, Inc.